- Our Story
- In Memory
Steve Wagner, Ph.D.
Principal Investigator, Department of Neurosciences, School of Medicine, University of California, San Diego
Dr. Wagner joined the Department of Neurosciences in the School of Medicine at the University of California, San Diego in June of 2009. Prior to that Dr. Wagner co-founded TorreyPines Therapeutics, then named Neurogenetics, in 2000 serving as its Chief Scientific Officer for nine years. Previously, Dr. Wagner was the Director of Protein Biochemistry at SIBIA Neurosciences from 1991-1999. He served as the program head of SIBIA’s Alzheimer’s disease drug discovery collaboration with Bristol-Myers Squibb (BMS). This collaboration resulted in the first gamma-secretase inhibitor for Alzheimer’s disease to reach the clinic. Dr. Wagner was a member of SIBIA’s Strategic Planning and Drug Discovery Steering Committees and a member of the Joint Steering Committee between SIBIA and BMS. Dr. Wagner is an inventor on numerous patents and patent applications and has published over 50 chapters and research papers in the top scientific journals. Prior to leading SIBIA’s Alzheimer’s disease drug discovery efforts, Dr. Wagner was a Research Associate Professor in the Department of Microbiology and Molecular Genetics at the University of California at Irvine where he co-authored the initial purification and identification of the human amyloid precursor protein (APP). Dr. Wagner received his B.S. in chemistry from Bellarmine College and received his M.S. and Ph.D. in biochemistry from the Health Sciences Center at the University of Louisville School of Medicine.
Project Description Researchers Funding Novel Soluble Gamma-Secretase Modulators for the Treatment of Alzheimer’s Disease Identification of the Molecular Target of Potent Gamma-Secretase Modulators
The goal of this project is to identify a series of highly potent gamma-secretase modulators able to lower Abeta42 and Abeta40 production while concomitantly increasing the less toxic production of Abeta38 without measurably affecting gamma-secretase-mediated processing of the Notch 1 receptor (which is very important in a variety of cellular processes for cell-to-cell communication).
Steve Wagner, Ph.D. 2011 - 2012
Novel Soluable Gamma-Secretase Modulators
Building on in vitro characterization of a novel series of soluable gamma-secretase modulators (SGSMs) funded by Cure Alzheimer’s Fund, the current project is a thorough pharmacological or in vivo examination of these molecules to identify the best or “lead” drug candidate.Steve Wagner, Ph.D.Rudy Tanzi, Ph.D.
Design, Synthesis and Characterization of Novel and Potent Gamma Secretase Modulators: Physiochemical and Pharmacokinetic Properties
During the past year, our laboratory at UCSD (Wagner laboratory), in close collaboration with the Tanzi laboratory at MGH, discovered, synthesized and characterized (in vitro) a novel series of molecules able to potently prevent the formation of what is currently thought to be the pathogenic culprit of Alzheimer’s disease (AD).Steve Wagner, Ph.D.William Mobley, MD, Ph.D.
These published papers resulted from Cure Alzheimer’s Fund support."Genome-wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOE" , Am. J. Hum. Genet. , 83 , November 2008 , 623-632,